EP0817779B1 - Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
EP0817779B1
EP0817779B1 EP96909192A EP96909192A EP0817779B1 EP 0817779 B1 EP0817779 B1 EP 0817779B1 EP 96909192 A EP96909192 A EP 96909192A EP 96909192 A EP96909192 A EP 96909192A EP 0817779 B1 EP0817779 B1 EP 0817779B1
Authority
EP
European Patent Office
Prior art keywords
radical
carbon atoms
general formula
radicals
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96909192A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0817779A1 (fr
Inventor
Hervé Bouchard
Jean-Dominique Bourzat
Alain Commerçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9503545A external-priority patent/FR2732340B1/fr
Priority claimed from FR9515381A external-priority patent/FR2742754B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to SI9630132T priority Critical patent/SI0817779T1/xx
Publication of EP0817779A1 publication Critical patent/EP0817779A1/fr
Application granted granted Critical
Publication of EP0817779B1 publication Critical patent/EP0817779B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the aryl radicals which can be represented by R 3 are phenyl or ⁇ - or ⁇ -naphthyl radicals optionally substituted by one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and the radicals alkyls, alkenyls, alkynyls, aryls, arylalkyls, alkoxy, alkylthio, aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkyloyamino carboxy, dialcoylamino carboxycarbyl nitro and trifluoro-methyl, it being understood that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, that the alkenyl and alkynyl radicals
  • the heterocyclic radicals which can be represented by R 3 are aromatic heterocyclic radicals having 5 chains and containing one or more atoms, identical or different, chosen from nitrogen, oxygen or sulfur atoms, optionally substituted by one or several substituents, identical or different, chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl radicals containing 1 to 4 carbon atoms, aryls containing 6 to 10 carbon atoms, alkoxy containing 1 to 4 atoms carbon, aryloxy containing 6 to 10 carbon atoms, amino, alkylamino containing 1 to 4 carbon atoms, dialkoylamino each alkyl part of which contains 1 to 4 carbon atoms, acylamino of which acyl part contains 1 to 4 carbon atoms, alkoxycarbonylamino containing 1 to 4 carbon atoms, acyl containing 1 to 4 carbon atoms, arylcarbonyl the aryl part of which contains 6
  • radicals R 4 and R 5 which may be identical or different, represent straight or branched alkoxy radicals containing 1 to 6 carbon atoms optionally substituted by a methoxy, ethoxy, ethylthio, carboxy, methoxycarbonyl, ethoxycarbonyl, cyano, carbamoyl radical, N -methyl-carbamoyl, N-ethylcarbamoyl, N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, N-pyrrolidino-carbonyl or N-piperidinocarbonyl.
  • the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R 1 represents a benzoyl radical or a radical R 2 -O- CO- in which R 2 represents a tert-butyl radical and R 3 represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, furyl-2, furyl-3, thienyl-2, thienyl-2, thiazolyl-2 radical, thiazolyl- 4 or thiazolyl-5, R 4 and R 5 , identical or different, each represent a methoxy, ethoxy or propoxy radical.
  • the new products of general formula (I) in which Z represents a radical of general formula (II) can be obtained by esterification of a product of general formula: in which R 4 and R 5 are defined as above, by means of an acid of general formula: in which R 1 and R 3 are defined as above, or else R 6 represents a hydrogen atom and R 7 represents a protective group for the hydroxy function, and either R 6 and R 7 together form a saturated heterocycle at 5 or 6 chains, or a derivative of this acid to obtain an ester of general formula: in which R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as above, followed by the replacement of the protective groups represented by R 7 and / or R 6 and R 7 by hydrogen atoms.
  • Esterification with an acid of general formula (IV) can be carried out in the presence of a condensing agent (carbodiimide, reactive carbonate) and an activating agent (aminopyridines) in an organic solvent (ether, ester, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature between -10 and 90 ° C.
  • a condensing agent carbbodiimide, reactive carbonate
  • an activating agent aminopyridines
  • organic solvent ether, ester, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons
  • Esterification can also be carried out using the acid of formula general (IV) in the form of symmetrical anhydride, operating in the presence of an agent activation (aminopyridines) in an organic solvent (ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature between 0 and 90 ° C.
  • an agent activation aminopyridines
  • organic solvent ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons
  • Esterification can also be carried out using the acid of formula general (IV) in the form of halide or in the form of mixed anhydride with a aliphatic or aromatic acid, optionally prepared in situ, in the presence of a base (tertiary aliphatic amine) by operating in an organic solvent (ethers, esters, ketones, nitriles, aliphatic hydrocarbons, aliphatic hydrocarbons halogenated, aromatic hydrocarbons) at a temperature between 0 and 80 ° C.
  • a base tertiary aliphatic amine
  • R 6 represents a hydrogen atom and R 7 represents a protective group for the hydroxy function or else R 6 and R 7 together form a saturated heterocycle with 5 or 6 links.
  • R 7 preferably represents a methoxymethyl, 1-ethoxy-ethyl, benzyloxymethyl, trimethylsilyl, triethylsilyl, ⁇ -trimethylsilylethoxymethyl, benzyloxycarbonyl or tetrahydropyrannyl radical.
  • R 6 and R 7 together form a heterocycle, the latter is preferably an optionally mono-substituted or gem-disubstituted oxazolidine ring in position -2.
  • the products of general formula (III), that is to say the products of general formula (I) in which Z represents a hydrogen atom, R 4 and R 5 are defined as above, can be obtained from 10-deacetyl-baccatin III of formula:
  • a silylated diether which can be obtained by the action of a silyl halide of general formula: (R) 3 -Si-Hal in which the symbols R, which are identical or different, represent an alkyl radical containing 1 to 6 carbon atoms optionally substituted by a phenyl radical, or a cycloalkyl radical containing 3 to 6 carbon atoms or a phenyl radical, on the 10-deacetyl- baccatine III to obtain a product of general formula: in which R is defined as above, then action of a product of general formula: R ' 4 -X 1 in which R ' 4 represents a radical such that R' 4 -O is identical to R 4 defined as above and X 1 represents a reactive ester residue such as a sulfuric or sulfonic ester residue or a halogen atom to obtain a product of general formula: in which R and R 4
  • a silylated derivative of general formula (X) on the 10-deacetyl-baccatin III is carried out in pyridine or triethylamine optionally in the presence of an organic solvent such as an aromatic hydrocarbon such as benzene, toluene or xylenes at a temperature between 0 ° C and the reflux temperature of the reaction mixture.
  • an organic solvent such as an aromatic hydrocarbon such as benzene, toluene or xylenes
  • a product of general formula (XII) on a product of general formula (XI) is carried out, after metallation of the hydroxy function into position 10 by means of an alkali metal hydride such as sodium hydride, a alkali metal amide such as lithium amide or an alkali metal alkyl such as butyllithium, operating in an organic solvent such as dimethylformamide or tetrahydrofuran at a temperature between 0 and 50 ° C.
  • an alkali metal hydride such as sodium hydride
  • a alkali metal amide such as lithium amide
  • an alkali metal alkyl such as butyllithium
  • the replacement of the silylated protective groups of the product of general formula (XIII) by hydrogen atoms is carried out by means an acid such as hydrofluoric acid or trifluoroacetic acid in the presence of a base such as triethylamine or pyridine optionally substituted by one or several alkyl radicals containing 1 to 4 carbon atoms, possibly associated with an inert organic solvent such as a nitrile such as acetonitrile or a halogenated aliphatic hydrocarbon such as dichloromethane at a temperature between 0 and 80 ° C.
  • a base such as triethylamine or pyridine
  • an inert organic solvent such as a nitrile such as acetonitrile or a halogenated aliphatic hydrocarbon such as dichloromethane at a temperature between 0 and 80 ° C.
  • the products of general formula (I) in which Z represents a radical of general formula (II), R 4 is defined as above and R 5 is defined as previously can be obtained from a product of general formula: in which R 1 , R 3 , R 6 and R 7 are defined as above by silylation in position 7 using a product of general formula (X) to obtain a product of general formula: in which R, R 1 , R 3 , R 6 and R 7 are defined as above, which is functionalized in position 10 by means of a product of general formula (XII) to give a product of general formula: in which R, R 1 , R 3 , R 4 , R 6 and R 7 are defined as above, the silylated protective group of which is replaced by a hydrogen atom to give a product of general formula: which, by the action of a product of general formula (XV) leads to the product of general formula (V) whose protective groups are replaced by hydrogen atoms to give a product of general formula (I) in which Z represents a
  • silylation, functionalization and replacement reactions of protective groups by hydrogen atoms are carried out in conditions similar to those described above.
  • the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) can be obtained by the action of activated Raney nickel in the presence of an aliphatic alcohol containing 1 with 3 carbon atoms or an ether such as tetrahydrofuran or dioxane on a product of general formula: in which R4 is defined as above, R 'and R ", identical or different, represent a hydrogen atom or an alkyl radical containing 1 to 6 carbon atoms, alkenyl containing 2 to 6 carbon atoms, alkynyl containing 2 to 6 carbon atoms, cycloalkyl containing 3 to 6 carbon atoms or cycloalkenyl containing 3 to 6 carbon atoms optionally substituted, or else R 'and R "together form with the carbon atom to which they are linked a cycloalkyl radical containing 3 to 6 carbon atoms or a cycloalkenyl radical containing 4 to 6 carbon
  • the action of activated Raney nickel in the presence of an alcohol aliphatic or ether is carried out at a temperature between -10 and 60 ° C.
  • the product of general formula (XXI) in which Z 1 and R 4 are defined as above can be obtained by the action of a sulfoxide of general formula: in which R 'and R "are defined as above, on a product of general formula (XIX).
  • reaction of the sulfoxide of general formula (XXIV), preferably dimethyl sulfoxide, on the product of general formula (XIX) is carried out in presence of a mixture of acetic acid and acetic anhydride or a derivative of acetic acid such as haloacetic acid at a temperature between 0 and 50 ° C, preferably around 25 ° C.
  • the products of general formula (I) obtained by the implementation of the process according to the invention can be purified according to known methods such as crystallization or chromatography.
  • the new products of general formula (I) obtained by the implementation work of the methods according to the invention can be purified according to the methods known such as crystallization or chromatography.
  • New products have anti-tumor properties and more particularly activity on tumors that are resistant to Taxol® or Taxotère®.
  • Such tumors include colon tumors which have a high expression of the mdr 1 gene (multi-drug resistance gene).
  • the multi-drug resistance is a common term referring to the resistance of a tumor to different products of different structures and mechanisms of action.
  • Taxoids are generally known to be highly recognized by experimental tumors such as P388 / DOX, a cell line selected for its resistance to doxorubicin (DOX) which expresses mdr 1.
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 dihydroxy-1 ⁇ , 13 ⁇ dimethoxy-7 ⁇ , 10 ⁇ oxo-9 taxene-11 (or 7 ⁇ , 10 ⁇ -dimethoxy 10-deacetoxy-baccatin III) can be prepared as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 trihydroxy-1 ⁇ , 7 ⁇ , 13 ⁇ methoxy-10 ⁇ oxo-9 taxene-11 (or 10 ⁇ -methoxy 10-deacetoxy-baccatin III) can be prepared as follows :
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-1 ⁇ methoxy-10 ⁇ oxo-9 bistriethylsilyloxy-7 ⁇ , 13 ⁇ taxene-11 (or 10 ⁇ -methoxy 10-deacetoxy 7,13-bistriethylsilyl-baccatin III) can be prepared as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 dihydroxy-1 ⁇ , 10 ⁇ oxo-9 bistriethylsilyloxy-7 ⁇ , 13 ⁇ taxene-11 (or 10-deacetyl 7,13-bistriethylsilyl-baccatin (III) can be prepared as follows:
  • the reaction medium is kept under stirring for 24 hours at a temperature in the region of 20 ° C then filtered through glass sintered.
  • the sintered glass is washed with 4 times 80 cm3 of ethanol, the filtrates are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C.
  • 710 mg of a yellow meringue which is purified by chromatography on 60 g of silica (0.063-0.2 mm) contained in a column 2.5 cm in diameter [eluent: dichloromethane-acetate ethyl (90-10 by volume)] by collecting fractions of 6 cm3.
  • Fractions do containing the desired product are combined and concentrated to dryness under pressure reduced (2.7 kPa) at 40 ° C.
  • tert-butoxycarbonyl-3 (methoxy-4) are thus obtained.
  • the reaction mixture is kept stirring for 7 days at a temperature around 20 ° C then poured into a mixture of 500 cm3 of distilled water and of 250 cm3 of dichloromethane. 30 cm3 are then added with good stirring of a saturated aqueous solution of potassium carbonate up to a pH close to 7. After 10 minutes of stirring, the organic phase is separated by decantation and re-extracts the aqueous phase with 2 times 250 cm3 of dichloromethane. The phases organics are combined, washed with 250 cm3 of distilled water, dried over sulphate magnesium, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C.
  • Tert-butoxycarbonyl-3 (4-methoxyphenyl) -2 phenyl-4 oxazolidine-1,3 carboxylate-5 (2R, 4S, 5R) acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 trihydroxy-1 ⁇ , 7 ⁇ , 10 ⁇ oxo-9 taxene-11 yle-13 ⁇ can be prepared as follows:
  • reaction mixture is then stirred for 15 minutes at 60 ° C then cooled to a temperature close to 20 ° C and filtered through sintered glass garnished with celite.
  • the sintered glass is washed with 2 times 15 cm 3 of methanol.
  • the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at a temperature close to 40 ° C.
  • To the residue are added 50 cm3 of ethyl acetate and 25 cm3 of a saturated aqueous solution of sodium hydrogencarbonate.
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 ethoxy-10 ⁇ dihydroxy-1 ⁇ , 13 ⁇ methoxy-7 ⁇ oxo-9 taxene-11 (or ethoxy-10 ⁇ methoxy-7 ⁇ deacetoxy-10 baccatin III) can be prepared as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 trihydroxy-1 ⁇ , 7 ⁇ , 13 ⁇ ethoxy-10 ⁇ oxo-9 taxene-11 (or ethoxy-10 ⁇ deacetoxy-10 baccatin III) can be prepared from as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-1 ⁇ ethoxy-10 ⁇ oxo-9 bistriethylsilyloxy-7 ⁇ , 13 ⁇ taxene-11 (or ethoxy-10 ⁇ deacetoxy-10 bistriethylsilyl-7.13 baccatin III) can be prepared as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 (propyl-1) oxy-10 ⁇ dihydroxy-1 ⁇ , 13 ⁇ methoxy-7 ⁇ oxo-9 taxene-11 (or (propyl-1) oxy-10 ⁇ methoxy-7 ⁇ deacetoxy-10 baccatin III) can be prepared as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 trihydroxy-1 ⁇ , 7 ⁇ , 13 ⁇ (propyl-1) oxy-10 ⁇ oxo-9 taxene-11 (or (propyl-1) oxy-10 ⁇ deacetoxy-10 baccatin III) can be prepared as follows:
  • Acetoxy-4 ⁇ benzoyloxy-2 ⁇ epoxy-5 ⁇ , 20 hydroxy-1 ⁇ (propyl-1) oxy-10 ⁇ oxo-9 bistriethylsilyloxy-7 ⁇ , 13 ⁇ taxene-11 (or (propyl-1) oxy-10 ⁇ deacetoxy-10 bistriethylsilyl-7.13 baccatin III) can be prepared as follows:
  • the new products of general formula (I) in which Z represents a radical of general formula (II) demonstrate a significant inhibitory activity on the abnormal cell proliferation and have therapeutic properties allowing the treatment of patients with pathological conditions associated with abnormal cell proliferation.
  • Pathological conditions include proliferation abnormal cell of malignant or non-malignant cells of various tissues and / or organs, including, but not limited to, muscle, bone or connectives, skin, brain, lungs, sex organs, systems lymphatic or renal, mammary or blood cells, liver, apparatus digestive, pancreas and thyroid or adrenal glands.
  • These conditions pathologies can also include psoriasis, solid tumors, cancers ovary, breast, brain, prostate, colon, stomach, kidney or testicles, Kaposi's sarcoma, cholangiocarcinoma, choriocarcinoma, neuroblastoma, Wilms tumor, Hodgkin's disease, melanomas, multiple myeloma, chronic lymphocytic leukemia, lymphoma acute or chronic granulocytic.
  • the new products according to the invention are particularly useful for the treatment of ovarian cancer. Products according to the invention can be used to prevent or delay the onset or recurrence of pathological conditions or to treat these conditions pathological.
  • the products according to the invention can be administered to a patient according to different forms adapted to the chosen route of administration which, preferably, is the parenteral route.
  • Parenteral administration includes administrations intravenous, intraperitoneal, intramuscular or subcutaneous. More specifically preferred is intraperitoneal or intravenous administration.
  • the present invention also includes pharmaceutical compositions which contain at least one product of general formula (I) in an amount sufficient suitable for use in human or veterinary therapy.
  • the compositions can be prepared according to the usual methods using one or several pharmaceutically acceptable adjuvants, carriers or excipients.
  • the suitable carriers include diluents, sterile aqueous media and miscellaneous non-toxic solvents.
  • the compositions are in the form of aqueous solutions or suspensions, injectable solutions which may contain emulsifying agents, dyes, preservatives or stabilizers.
  • the compositions can also be presented in the form of tablets, pills, powders or granules for oral administration.
  • adjuvants or excipients can be determined by the solubility and the chemical properties of the product, the particular mode of administration and the good pharmaceutical practices.
  • solutions or suspensions are used aqueous or non-aqueous sterile.
  • non-aqueous can be used natural vegetable oils such as oil olive, sesame oil or paraffin oil or injectable organic esters such as than ethyl oleate.
  • Aqueous sterile solutions can consist of a solution of a pharmaceutically acceptable salt in solution in water.
  • the aqueous solutions are suitable for intravenous administration since the pH is suitably adjusted and where isotonicity is achieved, for example, by a sufficient amount of sodium chloride or glucose. Sterilization can be performed by heating or by any other means which does not alter the composition.
  • compositions can contain at least 0.01% of therapeutic product active.
  • the amount of active product in a composition is such that a a suitable dosage can be prescribed.
  • the compositions are prepared in such a way that a unit dose contains from about 0.01 to 1000 mg of active product for parenteral administration.
  • Therapeutic treatment can be carried out concurrently with other therapeutic treatments including antineoplastic drugs, antibodies monoclonals, immunological therapies or radiotherapies or modifiers of biological responses.
  • Response modifiers include, without limitation, lymphokines and cytokines such as interleukins, interferons ( ⁇ , ⁇ or ⁇ ) and TNF.
  • chemotherapeutic agents useful in the treatment of disorders due to abnormal proliferation of cells include, without limitation, alkylating agents such as nitrogen mustards such as mechlorethamine, cyclophosphamide, melphalan and chlorambucil, alkyl sulfonates such as busulfan, nitrosoureas such as carmustine, lomustine, semustine and streptozocin, triazenes such as dacarbazine, antimetabolites such as folic acid analogs such as methotrexate, pyrimidine analogs like fluorouracil and cytarabine, analogs of purines such as mercaptopurine and thioguanine, natural products such as vinca alkaloids such as vinblastine, vincristine and vindesine, epipodophyllotoxins like etoposide and teniposide, antibiotics like dactinomycin, daunorubicin, doxorubicin, bleomycin, plica
  • the doses used to implement the methods according to the invention are those which allow a prophylactic treatment or a maximum response therapeutic. Doses vary depending on the form of administration, the particular product selected and the specific characteristics of the subject to be treated. In general, the doses are those which are therapeutically effective for the treatment of disorders due to a abnormal cell proliferation.
  • the products according to the invention can be administered as often as necessary to achieve the desired therapeutic effect. Some patients may respond quickly to relatively large doses or low then need low or no maintenance doses. Generally, from low doses will be used at the start of treatment and, if necessary, higher doses stronger will be administered until an optimum effect is obtained. For others patients it may be necessary to administer maintenance doses 1 to 8 times a day, preferably 1 to 4 times, depending on the physiological needs of the patient concerned. It is also possible that for some patients it is necessary to use only one or two daily administrations.
  • the doses are generally between 0.01 and 200 mg / kg. Doses will generally be between 0.1 intraperitoneally and 100 mg / kg and, preferably between 0.5 and 50 mg / kg and, even more specifically between 1 and 10 mg / kg. Intravenously, doses are generally understood between 0.1 and 50 mg / kg and, preferably between 0.1 and 5 mg / kg and, even more specifically between 1 and 2 mg / kg. It is understood that, to choose the most appropriate dosage appropriate, the route of administration, the patient's weight should be taken into account, general health, age and all factors that may affect the effectiveness of the treatment.
  • Example 2 40 mg of the product obtained in Example 1 are dissolved in 1 cm 3 of Emulphor EL 620 and 1 cm3 of ethanol then the solution is diluted by adding 18 cm3 of serum physiological.
  • composition is administered by infusion for 1 hour by introduction into physiological solution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP96909192A 1995-03-27 1996-03-25 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent Expired - Lifetime EP0817779B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9630132T SI0817779T1 (en) 1995-03-27 1996-03-25 Novel taxoids, preparation thereof and pharmaceutical compositions containing same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9503545 1995-03-27
FR9503545A FR2732340B1 (fr) 1995-03-27 1995-03-27 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR9515381 1995-12-22
FR9515381A FR2742754B1 (fr) 1995-12-22 1995-12-22 Procede de preparation de taxoides
PCT/FR1996/000440 WO1996030355A1 (fr) 1995-03-27 1996-03-25 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EP0817779A1 EP0817779A1 (fr) 1998-01-14
EP0817779B1 true EP0817779B1 (fr) 2000-01-05

Family

ID=26231838

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96909192A Expired - Lifetime EP0817779B1 (fr) 1995-03-27 1996-03-25 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP96909193A Expired - Lifetime EP0817780B1 (fr) 1995-03-27 1996-03-25 Nouveaux taxo des, leur preparation et les compositions pharmaceutiques qui les contiennent

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96909193A Expired - Lifetime EP0817780B1 (fr) 1995-03-27 1996-03-25 Nouveaux taxo des, leur preparation et les compositions pharmaceutiques qui les contiennent

Country Status (41)

Country Link
US (3) US5889043A (es)
EP (2) EP0817779B1 (es)
JP (2) JP2941951B2 (es)
KR (2) KR100485309B1 (es)
CN (2) CN1213042C (es)
AP (2) AP785A (es)
AR (1) AR001440A1 (es)
AT (2) ATE188471T1 (es)
AU (2) AU703278B2 (es)
BG (2) BG63121B1 (es)
BR (2) BR9607929A (es)
CA (2) CA2214321C (es)
CO (1) CO4700576A1 (es)
CZ (2) CZ287468B6 (es)
DE (2) DE69604653T2 (es)
DK (2) DK0817779T3 (es)
DZ (1) DZ2009A1 (es)
EA (2) EA000567B1 (es)
EE (2) EE03608B1 (es)
ES (2) ES2140075T3 (es)
GE (2) GEP20002211B (es)
GR (2) GR3031526T3 (es)
HU (2) HU223732B1 (es)
IL (1) IL117636A (es)
IS (2) IS2058B (es)
MA (1) MA23823A1 (es)
MY (1) MY121225A (es)
NO (2) NO316379B1 (es)
NZ (2) NZ304901A (es)
OA (2) OA10513A (es)
PE (1) PE51097A1 (es)
PL (2) PL188284B1 (es)
PT (1) PT817779E (es)
RO (2) RO115878B1 (es)
SK (2) SK281927B6 (es)
TN (1) TNSN96043A1 (es)
TR (2) TR199701040T1 (es)
TW (1) TW394765B (es)
UY (2) UY24192A1 (es)
WO (2) WO1996030356A1 (es)
ZA (1) ZA962399B (es)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051894A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
EP2491925A1 (en) 2011-02-25 2012-08-29 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
WO2012113897A1 (en) 2011-02-25 2012-08-30 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
EP2620148A1 (en) 2012-01-27 2013-07-31 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
WO2016133387A1 (en) 2015-02-17 2016-08-25 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US7288665B1 (en) * 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
FR2771092B1 (fr) * 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
IL141231A0 (en) * 1998-08-20 2002-03-10 Aventis Pharma Sa New use of taxoid derivatives
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives
EP1020188A1 (en) * 1999-01-13 2000-07-19 Aventis Pharma S.A. New use of taxoid derivatives
US6664275B2 (en) * 2000-02-02 2003-12-16 Fsu Research Foundation, Inc. C10 heterosubstituted acetate taxanes
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
CZ2003837A3 (cs) 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
AU2001290636A1 (en) * 2000-09-22 2002-04-02 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
CA2526278A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US7064980B2 (en) * 2003-09-17 2006-06-20 Sandisk Corporation Non-volatile memory and method with bit line coupled compensation
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
SV2006002010A (es) * 2004-02-13 2006-08-23 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
GT200500025A (es) * 2004-02-13 2005-09-30 Taxanos sustituidos con esteres de ciclopentilo en c10
JP2008530122A (ja) * 2005-02-14 2008-08-07 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド Ｃ１０シクロプロピルエステル置換タキサン組成物
RS52438B (en) * 2005-03-31 2013-02-28 Accord Healthcare Inc. PREPARATION OF 9-DIHYDRO-13-ACETYLBACCATINE TAXAN III
US8207358B2 (en) * 2005-11-04 2012-06-26 Accord Healthcare Ltd. Methods for the preparation of taxanes using chiral auxiliaries
US7847111B2 (en) * 2006-06-19 2010-12-07 Canada Inc. Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2173732A4 (en) * 2007-07-04 2011-09-07 Reddys Lab Ltd Dr PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2276755A4 (en) * 2008-03-31 2011-05-04 Univ Florida State Res Found C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
CN104208716A (zh) * 2009-11-23 2014-12-17 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US8791279B2 (en) * 2010-12-13 2014-07-29 Yung Shin Pharm. Ind. Co., Ltd. Process for preparing taxoids from baccatin derivatives using lewis acid catalyst
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088433A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Deuterated and/or fluorinated taxane derivatives
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN102060815B (zh) * 2010-12-24 2012-09-26 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
JP2014514306A (ja) * 2011-04-12 2014-06-19 プラス・ケミカルス・エスアー 固体形態のカバジタキセル及びその製造方法
AU2012290979A1 (en) 2011-08-02 2014-02-13 Astellas Pharma Inc. Method for treating cancer by combined use of medicinal agents
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
WO2013069027A1 (en) * 2011-09-26 2013-05-16 Fresenius Kabi Oncology Ltd. Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation
CN102336726B (zh) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 一种卡巴他赛的制备方法
US20130090484A1 (en) * 2011-10-11 2013-04-11 Scinopharm Taiwan Ltd. Process for making an intermediate of cabazitaxel
CN102408397B (zh) 2011-10-19 2014-08-20 上海贝美医药科技有限公司 紫杉烷类衍生物及其制备方法
CN102516281B (zh) * 2011-10-20 2015-02-04 江苏红豆杉生物科技股份有限公司 一种10-脱乙酰基巴卡丁iii及其衍生物甲氧基化的方法
CN102603724B (zh) * 2011-10-20 2014-02-26 江苏红豆杉生物科技股份有限公司 二甲氧基紫杉烷类化合物纯化精制的方法
CN102424672A (zh) * 2011-10-20 2012-04-25 江苏红豆杉生物科技有限公司 脱保护基制备二甲氧基紫杉烷类化合物的方法
WO2013072766A2 (en) * 2011-10-31 2013-05-23 Scinopharm Taiwan, Ltd. Process for cabazitaxel and intermediates thereof
CN102417491B (zh) * 2011-10-31 2013-11-06 江苏红豆杉生物科技有限公司 以10-去乙酰基-巴卡丁iii为原料制备卡巴他赛的方法
DE112012004569T5 (de) * 2011-11-01 2014-08-14 Fresenius Kabi Oncology Ltd. Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
CN103159705B (zh) * 2011-12-12 2015-05-27 福建南方制药股份有限公司 卡巴他赛中间体的制备方法
WO2013088335A1 (en) 2011-12-13 2013-06-20 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
CN102532064B (zh) * 2011-12-13 2015-06-17 重庆泰濠制药有限公司 二甲氧基多西他赛的合成方法
CN104583189A (zh) * 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
CN102775435B (zh) * 2012-08-21 2015-04-08 江苏红豆杉生物科技股份有限公司 一种用于制备7,10-甲氧基多西他赛的中间体的合成方法
CN102775434B (zh) * 2012-08-21 2015-04-08 江苏红豆杉生物科技股份有限公司 一种7,10-二甲氧基紫杉烷化合物中间体的合成方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
KR101407353B1 (ko) * 2012-12-04 2014-06-17 주식회사 삼양바이오팜 10-디아세틸바카틴 iii으로부터 카바지탁셀을 고수율로 제조하는 새로운 방법 및 이를 위한 신규 중간체
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN104650012A (zh) * 2013-11-22 2015-05-27 天士力控股集团有限公司 一种紫杉烷类化合物
CN104086514A (zh) * 2014-06-19 2014-10-08 上海应用技术学院 紫杉醇衍生物及其制备方法
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
US20210038578A1 (en) 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2629819B1 (fr) 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5489601A (en) 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5739362A (en) 1991-09-23 1998-04-14 Florida State University Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
FR2696459B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
MX9308012A (es) 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
ZA94128B (en) * 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
DE69427706T2 (de) 1993-12-21 2001-10-25 University Of Hawaii, Honolulu Cryptophycine
ATE171170T1 (de) 1994-06-28 1998-10-15 Upjohn Co 7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
US6201140B1 (en) 1994-07-28 2001-03-13 Bristol-Myers Squibb Company 7-0-ethers of taxane derivatives
US5481018A (en) 1995-03-31 1996-01-02 The Dow Chemical Company Amino nitrile intermediate for the preparation of alanine diacetic acid
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051894A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
US10583110B2 (en) 2009-10-29 2020-03-10 Sanofi Mature Ip Antitumoral use of cabazitaxel
US10716777B2 (en) 2009-10-29 2020-07-21 Sanofi Mature Ip Antitumoral use of cabazitaxel
EP2491925A1 (en) 2011-02-25 2012-08-29 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
WO2012113897A1 (en) 2011-02-25 2012-08-30 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
EP2620148A1 (en) 2012-01-27 2013-07-31 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
WO2016133387A1 (en) 2015-02-17 2016-08-25 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
WO2016180943A1 (en) 2015-05-13 2016-11-17 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Also Published As

Publication number Publication date
RO115878B1 (ro) 2000-07-28
DE69604653T2 (de) 2000-05-31
TW394765B (en) 2000-06-21
US20020038038A1 (en) 2002-03-28
MA23823A1 (fr) 1996-10-01
NO316607B1 (no) 2004-03-08
AU711227B2 (en) 1999-10-07
DZ2009A1 (fr) 2002-10-23
CA2214321A1 (fr) 1996-10-03
AU5278196A (en) 1996-10-16
JP2941951B2 (ja) 1999-08-30
CZ303297A3 (cs) 1998-01-14
HUP9801204A3 (en) 2000-12-28
HU223666B1 (hu) 2004-11-29
UY24370A1 (es) 2001-10-25
NO973922D0 (no) 1997-08-26
HU223732B1 (hu) 2004-12-28
BG101918A (en) 1998-10-30
DE69606028T2 (de) 2000-08-10
PE51097A1 (es) 1997-12-22
HUP9801201A2 (hu) 2000-05-28
IS4567A (is) 1997-09-23
DE69606028D1 (de) 2000-02-10
HUP9801204A1 (hu) 2000-05-28
EA000567B1 (ru) 1999-12-29
EA199700269A1 (ru) 1998-04-30
HUP9801201A3 (en) 2000-12-28
EP0817780A1 (fr) 1998-01-14
DK0817779T3 (da) 2000-06-19
KR100297196B1 (ko) 2001-11-22
AR001440A1 (es) 1997-10-22
CZ287468B6 (en) 2000-12-13
EE9700323A (et) 1998-06-15
RO115877B1 (ro) 2000-07-28
GEP20002188B (en) 2000-07-25
NZ304900A (en) 1998-09-24
EA199700270A1 (ru) 1998-02-26
ATE188471T1 (de) 2000-01-15
NO973923D0 (no) 1997-08-26
OA10513A (fr) 2002-04-22
PL188284B1 (pl) 2005-01-31
BG101917A (en) 1998-10-30
SK130197A3 (en) 1998-04-08
EE03609B1 (et) 2002-02-15
MY121225A (en) 2006-01-28
PL322465A1 (en) 1998-02-02
BR9607930A (pt) 1998-06-02
US6387946B1 (en) 2002-05-14
MX9706568A (es) 1997-11-29
AU5278096A (en) 1996-10-16
IL117636A0 (en) 1996-07-23
AU703278B2 (en) 1999-03-25
CZ287326B6 (en) 2000-10-11
SK130297A3 (en) 1998-03-04
US6331635B1 (en) 2001-12-18
PL188987B1 (pl) 2005-05-31
TR199701040T1 (xx) 1998-01-21
EE9700315A (et) 1998-06-15
ES2140075T3 (es) 2000-02-16
CZ303097A3 (cs) 1998-01-14
CN1179775A (zh) 1998-04-22
JPH11500141A (ja) 1999-01-06
CA2214319A1 (fr) 1996-10-03
ATE185562T1 (de) 1999-10-15
NO973923L (no) 1997-08-26
EE03608B1 (et) 2002-02-15
DK0817780T3 (da) 2000-03-27
NO316379B1 (no) 2004-01-19
GR3032316T3 (en) 2000-04-27
IS2056B (is) 2005-10-14
KR19980703287A (ko) 1998-10-15
CN1152870C (zh) 2004-06-09
WO1996030355A1 (fr) 1996-10-03
ZA962399B (en) 1996-10-01
AP753A (en) 1999-07-21
CN1179776A (zh) 1998-04-22
BG63121B1 (bg) 2001-04-30
TNSN96043A1 (fr) 2005-03-15
US5889043A (en) 1999-03-30
EP0817779A1 (fr) 1998-01-14
CA2214319C (fr) 2004-02-17
BG63009B1 (bg) 2001-01-31
IL117636A (en) 2004-08-31
KR19980703357A (ko) 1998-10-15
SK281927B6 (sk) 2001-09-11
IS2058B (is) 2005-10-14
AP9701090A0 (en) 1997-10-31
TR199701042T1 (xx) 1998-01-21
MX9706278A (es) 1997-10-31
AP9701093A0 (en) 1997-10-31
CO4700576A1 (es) 1998-12-29
NZ304901A (en) 1998-12-23
PL322499A1 (en) 1998-02-02
AP785A (en) 1999-11-26
GR3031526T3 (en) 2000-01-31
EA000709B1 (ru) 2000-02-28
EP0817780B1 (fr) 1999-10-13
WO1996030356A1 (fr) 1996-10-03
GEP20002211B (en) 2000-08-25
IS4536A (is) 1997-07-31
SK281928B6 (sk) 2001-09-11
UY24192A1 (es) 1996-06-14
PT817779E (pt) 2000-04-28
CN1213042C (zh) 2005-08-03
JPH11502531A (ja) 1999-03-02
JP3790826B2 (ja) 2006-06-28
ES2143187T3 (es) 2000-05-01
DE69604653D1 (de) 1999-11-18
NO973922L (no) 1997-08-26
BR9607929A (pt) 1998-06-02
OA10514A (fr) 2002-04-22
KR100485309B1 (ko) 2005-10-12
CA2214321C (fr) 2008-01-22

Similar Documents

Publication Publication Date Title
EP0817779B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2238884C (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0673372B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0820448B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0885208B1 (fr) Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2698363A1 (fr) Nouveaux dérivés du taxane, leur préparation et les compositions qui les contiennent.
EP0821680B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0788492B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0764154A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0874838B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0764155B1 (fr) Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1996001259A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1996030373A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2214320C (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2732340A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1995033739A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970918

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 970918;LT PAYMENT 970918;LV PAYMENT 970918;SI PAYMENT 970918

17Q First examination report despatched

Effective date: 19981130

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19970918;LT PAYMENT 19970918;LV PAYMENT 19970918;SI PAYMENT 19970918

REF Corresponds to:

Ref document number: 188471

Country of ref document: AT

Date of ref document: 20000115

Kind code of ref document: T

RIN1 Information on inventor provided before grant (corrected)

Inventor name: COMMERCON,ALAIN

Inventor name: BOURZAT, JEAN-DOMINIQUE

Inventor name: BOUCHARD, HERVE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE SA

Ref country code: CH

Ref legal event code: EP

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20000106

REF Corresponds to:

Ref document number: 69606028

Country of ref document: DE

Date of ref document: 20000210

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: FRENCH

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20000110

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2143187

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: RHONE-POULENC RORER S.A. TRANSFER- AVENTIS PHARMA S.A.

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: PT

Ref legal event code: PD4A

Free format text: AVENTIS PHARMA S.A. FR

Effective date: 20011116

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 69606028

Country of ref document: DE

Representative=s name: DF-MP DOERRIES FRANK-MOLNIA & POHLMAN PATENTAN, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20150331

Year of fee payment: 20

Ref country code: DK

Payment date: 20150310

Year of fee payment: 20

Ref country code: PT

Payment date: 20150324

Year of fee payment: 20

Ref country code: DE

Payment date: 20150317

Year of fee payment: 20

Ref country code: ES

Payment date: 20150212

Year of fee payment: 20

Ref country code: NL

Payment date: 20150309

Year of fee payment: 20

Ref country code: CH

Payment date: 20150313

Year of fee payment: 20

Ref country code: IT

Payment date: 20150227

Year of fee payment: 20

Ref country code: FI

Payment date: 20150311

Year of fee payment: 20

Ref country code: IE

Payment date: 20150309

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150309

Year of fee payment: 20

Ref country code: GR

Payment date: 20150211

Year of fee payment: 20

Ref country code: GB

Payment date: 20150325

Year of fee payment: 20

Ref country code: AT

Payment date: 20150225

Year of fee payment: 20

Ref country code: SE

Payment date: 20150311

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20150311

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69606028

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20160325

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20160324

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20160325

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20160324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160324

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 188471

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160325

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 990402501

Country of ref document: GR

Effective date: 20160326

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160325

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160401